CD8A and neoplasm: As a result,therapeutic strategies incorporating anti-PD-L1 blockade have beenincreasingly employed to overcome the formidable challenge of therapeuticresistance in oncological interventions.−,  To evaluatethe effects of NP1192 combined with anti-PD-L1 antibody and NP1192or anti-PD-L1 blockade alone on CD8+ TILs, immunoflow cytometrywas performed after tumor excision.